Cardiovascular Journal of Africa: Vol 22 No 5 (September 2011) - page 6

REVATIO
®
...
A wEll EsTAblIshEd PdE-5 InhIbITOR REgIsTEREd
fOR usE In PulmOnARy ARTERIAl hyPERTEnsIOn (PAh)
REVATIO
®
helping your patients to do more...
Significantly improves exercise capacity (p<0.001)
(1)
Significantly reduces mean pulmonary arterial pressure (p=0.04)
(1)
Significantly improves physical functioning and general health (p<0.001)
(2)
...without holding them back
Convenient oral dosing: 20 mg tds with or without meals
Adverse events are generally mild to moderate
(1,3)
Low discontinuation rate comparable to placebo
(3)
No monthly liver function testing required
(3)
For full prescribing information, refer to the package insert
References: 1.
Galiè N,Ghofrani HA,TorbickiA,Barst RJ,Rubin LJ,Badesch D,
et al
.Sildenafil CitrateTherapy for PulmonaryArterial Hypertension.
N Engl J Med
2005;
353
(20):2148-2157.
2.
Pepke-Zaba J,Gilbert C,Collings L,Brown MCJ.Sildenafil Improves Health-Related Quality
of Life in Patients With Pulmonary Arterial Hypertension.
Chest
2008;
133
:183-189.
3.
Croom KF, Curran MP. Sildenafil.A Review of its Use in Pulmonary Arterial Hypertension.
Drugs
2008;
68
(3):338-397.
S4 REVATIO
®
Film-coated tablets (Reg. No.A40/7.1.5/0131).
COMPOSITION:
Each tablet contains 20 mg of sildenafil, as the citrate.
PHARMACOLOGICAL CLASSIFICATION:
A 7.1.5 Vasodilators – peripheral.
Pfizer Laboratories (Pty) Ltd. Reg. No.: 1954/000781/07. P.O. Box 783720, Sandton 2146.Tel. No.: 0860 PFIZER (734937). PI Ref: 13/07/09. 23/REV/11/10/JA
Start with it, stay with it.
1,2,3,4,5 7,8,9,10,11,12,13,14,15,16,...68
Powered by FlippingBook